NRD
TARS icon

Nebula Research & Development’s Tarsus Pharmaceuticals TARS Stock Holding History

Nebula Research & Development’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-17,684
Closed -$582K – 1108
2024
Q3 		$582K Buy
+17,684
New +$497K 0.07% 496

Other funds holding TARS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Nebula Research & Development's TARS Position: Q4 2024 in Review

Nebula Research & Development sold out of Tarsus Pharmaceuticals (TARS) in Q4 2024, closing a stake of 17,684 shares — an estimated $582K sold.

Nebula Research & Development first reported a position in TARS in Q3 2024 and held it in 1 quarter. The position peaked at $582K in Q3 2024. 195 funds tracked by Wall St. Rank hold TARS as of Q4 2024.

  • Nebula Research & Development reported no remaining Tarsus Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Nebula Research & Development sold 17,684 Tarsus Pharmaceuticals shares in Q4 2024, an estimated $582K.
  • Nebula Research & Development first reported a position in Tarsus Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Nebula Research & Development's Tarsus Pharmaceuticals position peaked at $582K in Q3 2024.
  • 195 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q4 2024.

Based on Nebula Research & Development's 13F filing for Q4 2024, filed 14 Feb 2025.